-
April 26, 2013
Celgene Corp has posted a healthy set of financials for the first quarter despite a 4.1% decline in net income to $410.2 million, as product sales increased 15% to $1.43 billion
Full story
-
February 21, 2013
Celgene Corp is using its considerable cashpile for another $600 million share buyback, meaning it has repurchased nearly $1 billion of stock already this year
Full story
-
February 14, 2013
By 2018, five new drugs will have launched for myelodysplastic syndromes (MDS), three of which are expected to offer much-needed second-line therapeutic options in the HMA-refractory higher-risk MDS population, says a new study.
Full story
-
January 08, 2013
As Celgene Corp presented the breadth and quality of its portfolio at the JPMorgan healthcare conference in San Francisco, the firm presented more positive clinical data for apremilast, this time for psoriasis
Full story
-
June 22, 2012
Celgene's shares took a plunge yesterday (thursday) after investors shrank back on news that the group has pulled its application in Europe to expand the scope of Revlimid for multiple myeloma (MM).
Full story
-
January 27, 2012
On a busy day for US dealmaking, Celgene Corp is to acquire privately-held Avila Therapeutics in a deal that could be worth up to $925 million
Full story
-
December 21, 2011
The market for drug therapies to treat multiple myeloma will experience robust growth averaging 5.6% a year from 2010 to 2020 in seven major world markets, according to new forecasts.
Full story
-
November 23, 2011
Celgene has called a halt to a late-stage trial of its oncology blockbuster Revlimid as a potential treatment for prostate cancer
Full story
-
August 16, 2011
The National Institute for Health and Clinical Excellence (NICE) will examine uses of Botox, Revlimid and Tarceva as part of its new work programme, Ministers have agreed.
Full story
-
May 24, 2011
Expensive new drugs treating increasing numbers of patients could drive US drug spending by as much as 15% a year to 2013, say new forecasts.
Full story